Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
U.S. judge questions scope of indictment against Insys founder

21h reuters
BOSTON (Reuters) - A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc (INSY.O) executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal.
INSY

0
US judge questions scope of indictment against Insys founder

21h channelnewsasia
A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal.
INSY

5
Zogenix's Epilepsy Candidate Successful in Phase III Study

2018-07-13 zacks
Zogenix, Inc. (ZGNX - Free Report) announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults.
GWPH SUMM INSY ZGNX SMMT SAM GWP

63
Swinging For The Fence On Antares Pharma

2018-07-08 seekingalpha
A study from 2009 by Alok Kumar found retail investors exhibit “a greater propensity to gamble” as compared to institutional investors.
ATRS MYL AMAG AZN TEVJF AZN IPXL INSY TEVA TEVVF ADMP

85
4 Drug and Biotech Stocks Awaiting FDA Decisions in July

2018-07-02 investorplace
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year.
VRTX AMGN JNJ INSY GSK PGNX

81
4 Drug and Biotech Stocks Awaiting FDA Decisions in July

2018-07-02 zacks
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year.
INVVY VRTX AMGN INSY IZQVF PGNX

5
Opioid makers cut back on marketing payment to doctors

2018-06-28 cnbc
The past two years have been a time of reckoning for pharmaceutical manufacturers over their role in promoting opioid drugs that have fed a national epidemic.
INSY BDSI

1
First Marijuana-Based Medicine Is Approved for Sale in U.S. - Bloomberg

2018-06-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
INSY GWP

3
D-Day Approaches For GW Pharma

2018-06-20 seekingalpha
In fact, company's long-term prospects should be predicated on the pipeline in general and not just specifically on epidiolex.
NMUS INSY GWP

0
INSYS Therapeutics Provides an Update on Its Ongoing Transformation

2018-06-18 globenewswire
PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company. Below is a synopsis of these ongoing efforts.
INSY

165
Your Daily Pharma Scoop: Resverlogix Cleared For Trial, ViiV Positive Data, Eli Lilly Up

2018-06-16 seekingalpha
Resverlogix (OTCPK:RVXCF) recently announced that the FDA has accepted the statistical analysis plan and endpoints for the large-scale Phase 3 trial of assessment of cardiovascular benefits of its lead candidate apabetalone. The projected endpoint of the study is the reduction of major adverse cardiovascular events (MACE) in a high cardiovascular risk in type 2 diabetes population. The same population often also displayed low levels of high density lipoproteins (HDL).
CTRV AMGN RVXCF MTFB APTO MTFB APS LLY TRIL RYTM GSK MYL MTFBF INSY LIVN CHMA

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

133
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

2018-06-13 globenewswire
CORAL GABLES, Fla., June 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Daniel J. Brennan as Chief Commercial Officer. Mr. Brennan will be responsible for leading the Company’s marketing, sales and commercial operations as Catalyst prepares for a potential launch of Firdapse®.
ABT CPRX EDGE INSY ABT

0
Florida doctor admits taking kickbacks from Insys, others

2018-06-04 reuters
June 4 (Reuters) - A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.
INSY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to INSY / Insys Therapeutics Inc. on message board site Silicon Investor.

Intrinsyc Software Inc. (T.ICS) (formerly V.ICS) INSN - InsynQ, Incorporated
INSY Intraco Systems
CUSIP: 45824V209